A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM
Summary
- Eligibility
- for people ages 18-100 (full criteria)
- Location
- at La Jolla, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Caitlin Costello, MD
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSD
- Caitlin Costello, MD
As a member of the Division of Blood and Marrow Transplantation, Dr Costello is dedicated to providing excellent care for patients with a variety of hematologic malignancies, with a specific focus in lymphoproliferative disorders and bone marrow transplantation. Dr Costello’s research interests focus particularly on the refinement of the management and treatment of multiple myeloma.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Harpoon Therapeutics
- ID
- NCT04184050
- Phase
- Phase 1 Multiple Myeloma Research Study
- Study Type
- Interventional
- Participants
- Expecting 70 study participants
- Last Updated